Clinical Research Directory
Browse clinical research sites, groups, and studies.
High-Dose Ambroxol in GBA1-Related Parkinson
Sponsor: Agyany Pharma LTD
Summary
Parkinson's disease (PD), affecting 10 million people globally, lacks a cure, and current therapies only manage symptoms. A link between Gaucher disease (GD) and PD, particularly in carriers of glucocerebrosidase (GBA1) mutations, has sparked interest in developing new drugs. Despite pharmaceutical companies focusing on formulations, progress is slow. Agyany, with decades of experience in GD research, plans clinical trials using existing generic drugs for GBA-related PD and idiopathic PD. Their approach targets the misfolded enzyme glucocerebrosidase with pharmacological chaperons, inspired by success in GD using ambroxol. The strategy aims to provide a quicker path to novel therapeutic options for PD.
Official title: An Open-Label Pilot Study for Assessing the Safety and Efficacy of High-Dose Ambroxol (HDA) in Newly Diagnosed GBA1 Parkinson Disease (PD)
Key Details
Gender
All
Age Range
30 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2023-10-24
Completion Date
2026-04-30
Last Updated
2026-11-09
Healthy Volunteers
No
Conditions
Interventions
Ambroxol Hydrochloride
75mg slow release (SR), X16/day or 300mg X4/day oral capsules.
Locations (1)
Shaare Zedek Medical Center
Jerusalem, Israel